Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
NCT00451451
First received: March 21, 2007
Last updated: May 5, 2014
Last verified: May 2014

March 21, 2007
May 5, 2014
June 2007
August 2011   (final data collection date for primary outcome measure)
Annualized Relapse Rate [ Time Frame: 2 years ] [ Designated as safety issue: No ]

A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee.

The adjusted annualized relapse rate was calculated from a negative binomial regression model , adjusted for baseline Expanded Disability Status Scale (EDSS ) score(≤2.0 versus>2.0), age (<40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.

To determine whether BG00012, when compared with placebo is effective in reducing the rate of clinical relapses at 2 years.
Complete list of historical versions of study NCT00451451 on ClinicalTrials.gov Archive Site
  • Number of New or Newly Enlarging T2 Hyperintense Lesions [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 hyperintense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T2 hyperintense lesion volume.
  • Number of New T1 Hypointense Lesions [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    The number of new T1 hypointense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T1 hypointense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T1 hypointense lesion volume.
  • Proportion of Subjects Relapsed [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.
  • Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or ≥1.5 point increase in subjects with a baseline EDSS=0, and required that the increase from baseline was confirmed ≥ 12weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution
There are multiple secondary outcomes.
Not Provided
Not Provided
 
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse.

Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.

Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects approximately 400,000 persons in North America and 365,000 persons in Europe. It is predominantly a disease of young adults, primarily women, with disease onset typically occurring between the ages of 20 and 40.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Relapsing-Remitting Multiple Sclerosis
  • Drug: BG00012
    Other Names:
    • dimethyl fumarate
    • Tecfidera®
  • Drug: Placebo
  • Drug: Glatiramer Acetate
  • Experimental: BG00012 240 mg Twice Daily (BID)
    Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)
    Interventions:
    • Drug: BG00012
    • Drug: Placebo
  • Experimental: BG00012 240 mg 3 Times Daily (TID)
    Participants received two 120 mg BG00012 capsules orally three times daily (TID)
    Intervention: Drug: BG00012
  • Placebo Comparator: Placebo
    Participants received two placebo capsules orally three times daily (TID)
    Intervention: Drug: Placebo
  • Active Comparator: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
    Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
    Intervention: Drug: Glatiramer Acetate

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1417
August 2011
August 2011   (final data collection date for primary outcome measure)

Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:

Key Inclusion Criteria:

  • Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4
  • Must have a baseline EDSS between 0.0 and 5.0, inclusive.
  • Must have relapsing-remitting disease course.

Key Exclusion Criteria:

  • Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease
  • Pregnant or nursing women

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Ukraine,   Belarus,   Belgium,   Bosnia and Herzegovina,   Bulgaria,   Canada,   Costa Rica,   Croatia,   Czech Republic,   Estonia,   France,   Germany,   Greece,   India,   Ireland,   Israel,   Latvia,   Macedonia, The Former Yugoslav Republic of,   Mexico,   Moldova, Republic of,   New Zealand,   Poland,   Puerto Rico,   Romania,   Serbia,   Slovakia,   Spain
 
NCT00451451
109MS302
Yes
Biogen Idec
Biogen Idec
Not Provided
Study Director: Medical Director Biogen Idec
Biogen Idec
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP